Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

A comparative analysis of SARS-CoV-2 antivirals in human airway models characterizes 3CL pro inhibitor PF-00835231 as a potential new treatment for COVID-19

bioRxiv (Cold Spring Harbor Laboratory)(2020)10.1101/2020.08.28.272880Source: DataRank Database

A comparative analysis of SARS-CoV-2 antivirals in human airway models characterizes 3CL pro inhibitor PF-00835231 as a potential new treatment for COVID-19 is a research paper published in bioRxiv (Cold Spring Harbor Laboratory) (2020). On theSindex it has a DataRank of 0. It has been cited 24 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access24 citations

Download PDF

Cite:

Linked data & code

geo gen rrid

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (4 grants)OA: greenTopics (29)IDs (PubMed, OpenAlex)Annotations (3)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (17)

Adil Mohamed ORCID,Rachel A. Prescott ORCID,Ana M. Valero-Jimenez ORCID,Ludovic Desvignes ORCID,Rebecca E. O’Connor ORCID

Live enrichment

PubMed:21097893 OpenAlex:https://openalex.org/W3082245868

National Institutes of Health

Grant: 1R21AI139374-01A1

SERPINs as a novel family of innate antiviral molecules - Resubmission - 1

National Institutes of Health

Grant: 5R01HL125816-04

Microbial triggers and molecular mechanisms of Th17 mediated airway inflammation-Resubmission-1

National Institutes of Health

Grant: 5P30CA016087-32

Experimental Pathology

National Institutes of Health

Grant: 5R01AI143639-04

ELF1 - Molecular mechanisms of a novel transcription factor with broad antiviral activity

greenLicense: cc-by-nd

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/7457613

repositoryhttps://www.biorxiv.org/content/biorxiv/early/2021/02/19/2020.08.28.272880.full.pdf

publisherhttps://syndication.highwire.org/content/doi/10.1101/2020.08.28.272880

Europe_PMChttps://europepmc.org/article/PPR/PPR207473

Europe_PMChttps://europepmc.org/api/fulltextRepo?pprId=PPR207473&type=FILE&fileName=EMS94343-pdf.pdf&mimeType=application/pdf

Fields of Study

SARS-CoV-2 and COVID-19 ResearchRespiratory viral infections researchSARS-CoV-2 detection and testing0301 basic medicine03 medical and health sciences

Keywords

A549 cellVero cellProtease inhibitor (pharmacology)PharmacologyVirologyCoronavirusViral life cycleAntiviral drugPotencyBiologyRespiratory epitheliumDrugVirusViral replicationRespiratory systemIn vitroMedicineCoronavirus disease 2019 (COVID-19)Viral loadBiochemistryPathologyDiseaseInfectious disease (medical specialty)Article

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Responsible consumption and production

A comparative analysis of SARS-CoV-2 antivirals in human airway models characterizes 3CL pro inhibitor PF-00835231 as a potential new treatment for COVID-19

FAIR Checklist

Authors (17)

Funding (4 grants)

Open Access

Topics

Annotations (Europe PMC)